



Prevention **NOW!**

October 29, 2020 - Issue 62



More than 800 participants joined the recent 2020 HPTN Update Webinar to learn about the state of the Network, community engagement successes, the HPTN Scholars program, presentations on placebo counterfactuals for PrEP and laboratory testing for SARS-CoV-2, and a discussion of our future research agenda. Keynote speaker Dr. Anthony S. Fauci kicked off the event with a prerecorded talk on COVID-19 public health and scientific challenges.

[View Webinar Replay](#)

**Thomas Fleming Receives Ward Cates Spirit
Award**



Dr. Thomas Fleming received the 2020 Ward Cates Spirit Award during the recent HPTN Update Webinar. He was acknowledged for his admirable dedication, passion, and tireless pursuit of ensuring clinical trials are well designed, properly implemented, and correctly interpreted. Dr. Fleming has generously given his time to develop capacity within the HPTN and elsewhere to understand the issues related to clinical trials through teaching both in U.S. and HPTN trial sites in Africa. The award honors the legacy of Dr. Willard (Ward) Cates Jr., a dedicated steward of the HPTN scientific and research programs, and a respected scientist who contributed to groundbreaking contraceptive and HIV prevention research.

[Read More](#)

HPTN Network Performance Awards

The HPTN Network Performance Awards, recognizing top performers in community engagement, study participant accrual and estimated retention, laboratory performance, and staff excellence in leadership, were announced during the 2020 HPTN Update Webinar. We congratulate all award recipients for their achievements.



[Read More](#)

Big Changes Ahead for HPTN.org



This fall, we are making some exciting changes to our website. These changes will include:

- An updated look to the website homepage
- An updated Community Engagement section
- A new Network PowerPoint presentation template
- No more website login

Private study documents will now be hosted on a Microsoft Team that you will be invited to within the next month.

[Read More](#)

Shoutout



The HPTN 094 INTEGRA study will test the use of a mobile clinic to deliver "one-stop" integrated health services – particularly medication for opioid use disorder (MOUD) and HIV treatment and prevention – to people who inject drugs in five U.S. cities. The study will measure the intervention's efficacy to improve uptake and use of MOUD, and uptake and use of antiretroviral therapy (ART) or pre-exposure prophylaxis (PrEP), and other objectives. The first mobile unit has been completed at the manufacturer in Arizona and will soon road trip more than 2000 miles to its new home at the Penn Prevention CRS in Philadelphia. The other four sites engaged in the study – Bronx Prevention Research Center CRS, George Washington University CRS, UCLA Vine Street Clinic CRS, and Houston AIDS Research Team CRS – are awaiting their mobile units, which are in process. The study is expected to start in early 2021.

Network Member Spotlight



Melissa M. Turner, MSW, LICSW, MPA, chair of the HPTN Community Working Group and HPTN Executive Committee member, has been integrally involved in patient care management and HIV clinical trials for more than 20 years. She is a clinical social worker in the Infectious Diseases Section at the Veterans Affairs Medical Center in Washington, D.C. Melissa is also the community advisory board liaison at the George Washington University HPTN CRS and community engagement specialist for HIV research trials at the local and international level for U.S.

National Institutes of Health-funded clinical trial networks. She recently joined the community working group for the newly formed COVID-19 Prevention Network (CoVPN). Melissa specializes in community education, bridging the divide between science and community, and works to integrate community needs and perspectives in all aspects of clinical trial design from conception, implementation and results dissemination.

[Read More](#)

Hot Off The Press

Viljoen L, Bond VA, Reynolds LJ, Mubekapi-Musadaidzwa C, Baloyi D, Ndubani R, Stangl A, Seeley J, Pliakas T, Bock P, Fidler S, Hayes R, Ayles H, Hargreaves JR, Hoddinott G; HPTN 071 (PopART) study team. [Universal HIV testing and treatment and HIV stigma reduction: a comparative thematic analysis of qualitative data from the HPTN 071 \(PopART\) trial in South Africa and Zambia](#). *Sociol Health Illn*. 2020 Oct 21.

Shanaube K, Schaap A, Hoddinott G, Mubekapi-Musadaidzwa C, Floyd S, Bock P, Hayes R, Fidler S, Ayles H; HPTN 071 (PopART) Study Team. [Impact of a community-wide combination HIV prevention intervention on knowledge of HIV status among adolescents](#). *AIDS*. 2020 Oct 8.

Maragh-Bass AC, Gamble T, El-Sadr WM, Hanscom B, Tolley EE. [Exploring individual-level barriers to HIV medication adherence among men who have sex with men in the HIV Prevention Trials Network \(HPTN 065\) study](#). *AIDS Care*. 2020 Oct 7:1-10.

Sandfort TG, L Hamilton E, Marais A, Guo X, Sugarman J, Chen YQ, Cummings V, Dadabhai S, Dominguez K, Panchia R, Schnabel D, Zulu F, Reynolds D, Radebe O, Mbede C, Kamba D, Kanyemba B, Ogendero A, Stirratt M, Chege W, Lucas J, Fawzy M, McKinstry LA, Eshleman SH. [The feasibility of recruiting and retaining men who have sex with men and transgender women in a multinational prospective HIV prevention research cohort study in sub-Saharan Africa \(HPTN 075\)](#). *J Int AIDS Soc*. 2020 Oct;23 Suppl 6(Suppl 6):e25600.

Kiriazova T, Go VF, Hershov RB, Hamilton EL, Sarasvita R, Bui Q, Lancaster KE, Dumchev K, Hoffman IF, Miller WC, Latkin CA. [Perspectives of clients and providers on factors influencing opioid agonist](#)

[treatment uptake among HIV-positive people who use drugs in Indonesia, Ukraine, and Vietnam: HPTN 074 study](#). Harm Reduct J. 2020 Oct 1;17(1):69.

Hargreaves JR, Pliakas T, Hoddinott G, Mainga T, Mubekapi-Musadaidzwa C, Donnell D, Piwowar-Manning E, Agyei Y, Bell-Mandla NF, Dunbar R, Macleod D, Floyd S, Bock P, Fidler S, Hayes RJ, Seeley J, Stangl A, Bond V, Ayles H. [HIV stigma and viral suppression among people living with HIV in the context of universal test and treat: analysis of data from the HPTN 071 \(PopART\) trial in Zambia and South Africa](#). J Acquir Immune Defic Syndr. 2020 Sep 24.



What would you like to see from our newsletters? Please e-mail us with your thoughts and ideas at news@hptn.org.

Copyright © 2020 The HIV Prevention Trials Network, All rights reserved.